FDA is modernizing how it works with data, and AI, machine learning (ML) and large language models (LLMs) such as ChatGPT are changing how medical device and SaMD products are built and reviewed. The agency set a June 2025 deadline for its centers to integrate generative AI and announced Elsa, a secure GovCloud tool that can summarize reports, help review safety data and flag facilities for inspection, with the aim of shortening submission reviews.
This 90-minute webinar explains how FDA and life science companies are using these tools, why LLMs act as a black box that depends on quality-checked data, and how the proposed VALID Act's firm-based approach would shift oversight to how products are developed. It covers SaMD Pre-Specifications and the Algorithm Change Protocol, the AI/ML SaMD Action Plan and GMLP, and the Total Product Lifecycle approach, where documented risk analysis can sometimes replace a new 510(k).
It also reviews computer system validation, FDA's Computer Software Assurance (CSA) approach, GAMP 5 Second Edition and software validation and maintenance.
AI, ML and LLMs bring a chance for greater efficiency in the software development life cycle, but they also add new challenges for companies that develop, test and support life science software. This webinar shows how these tools can support SDLC work and new device and SaMD products while staying compliant with FDA.
Attend if you plan, run, maintain or support FDA-regulated systems, or develop and test medical device or SaMD software, in pharma, devices, biologics, animal health or tobacco, in roles from IT and QA to regulatory affairs.
This webinar is intended for those involved in planning, execution, and support of computer system validation activities, working in the FDA-regulated industries, including pharmaceutical, medical device, biologics, tobacco, and tobacco-related products (e-liquids, e-cigarettes, pouch tobacco, cigars, etc.). Functions that are applicable include research and development, manufacturing, Quality Control, distribution, clinical testing and management, sample labeling, adverse events management, and post-marketing surveillance.
Personnel in the following roles will benefit:
Carolyn Troiano has more than 35 years of experience in computer system validation in the tobacco, pharmaceutical, medical device and other FDA-regulated industries. She has worked directly, or on a consulting basis, for many of the larger pharmaceutical and tobacco companies in the US and Europe. She is currently building an FDA computer system validation compliance strategy at a vapor company. Carolyn has participated in industry conferences, and is currently active in the Association of Information Technology Professionals (AITP), and Project Management Institute (PMI) chapters in the Richmond, VA area. Carolyn also volunteers for the PMI’s Educational Fund as a project management instructor for non-profit organizations.